Related Experiment Video
Updated: May 8, 2026

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
Published on: March 31, 2019
Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells
Anne Largeot1, Jérôme Paggetti2, Julien Broséus1
1Inserm U866, Labex LipSTIC team, Faculté de Médecine, Université de Bourgogne, 21000 Dijon, France.
Abstract:
MOZ and MLL encoding a histone acetyltransferase and a histone methyltransferase, respectively, are targets for recurrent chromosomal translocations found in acute myeloblastic or lymphoblastic leukemia. We have previously shown that MOZ and MLL cooperate to activate HOXA9 gene expression in hematopoietic stem/progenitors cells. To dissect the mechanism of action of this complex, we decided to identify new proteins interacting with MOZ. We found that the scaffold protein Symplekin that supports the assembly of polyadenylation machinery was identified by mass spectrometry. Symplekin interacts and co-localizes with both MOZ and MLL in immature hematopoietic cells. Its inhibition leads to a decrease of the HOXA9 protein level but not of Hoxa9 mRNA and to an over-recruitment of MOZ and MLL onto the HOXA9 promoter. Altogether, our results highlight the role of Symplekin in transcription repression involving a regulatory network between MOZ, MLL and Symplekin.
Insights
Symplekin, a protein involved in RNA processing, interacts with MOZ and MLL, key leukemia-associated proteins. This interaction influences HOXA9 gene expression, revealing Symplekin
Area of Science:
- Molecular Biology
- Hematopoiesis
- Cancer Biology
Background:
- MOZ and MLL are histone modifiers implicated in leukemia through chromosomal translocations.
- MOZ and MLL cooperate to regulate HOXA9 gene expression in hematopoietic stem/progenitor cells.
Purpose of the Study:
- To identify novel proteins interacting with MOZ to elucidate the MOZ-MLL complex's mechanism of action.
- To investigate the functional role of Symplekin in the context of MOZ and MLL function.
Main Methods:
- Mass spectrometry to identify MOZ-interacting proteins.
- Co-immunoprecipitation and immunofluorescence to confirm Symplekin-MOZ-MLL interactions and localization.
- Functional assays to assess the impact of Symplekin inhibition on HOXA9 expression and MOZ/MLL recruitment.
Main Results:
- Symplekin was identified as a MOZ-interacting protein and confirmed to interact and co-localize with MOZ and MLL in hematopoietic cells.
- Symplekin inhibition reduced HOXA9 protein levels without affecting Hoxa9 mRNA, suggesting post-transcriptional regulation.
- Symplekin inhibition led to increased recruitment of MOZ and MLL to the HOXA9 promoter.
Conclusions:
- Symplekin plays a crucial role in the transcriptional regulation network involving MOZ, MLL, and HOXA9.
- Symplekin's function in polyadenylation machinery assembly is linked to its role in MOZ/MLL-mediated gene repression.
- These findings uncover a novel regulatory mechanism in hematopoietic gene expression with implications for leukemia research.
Related Concept Videos
Pleiotropy
Inheritance of Chromatin Structures
Master Transcription Regulators
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Hedgehog Signaling Pathway
Abnormal Proliferation

